" class="no-js "lang="en-US"> Novartis Archives - Medtech Alert
Saturday, December 09, 2023

Sort by:


Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

Novartis Trial Shows Benefit in Patients with Breast Cancer

Novartis today announced positive topline results from an interim analysis of NATALEE, a Phase III […]

Dawn Health partners with leading Pharmaceutical Company, Novartis, to Transform Chronic Care

Dawn Health, a global leader in digital health, has announced a strategic partnership with Novartis, […]

Novartis Pharmaceuticals UK Launches World-first Health-tech Investor Partnership to Reimagine Cardiovascular Care

Novartis Pharmaceuticals UK announces the launch of the Novartis Biome UK Heart Health Catalyst 2022, […]

Novartis Receives GB Licence for Scemblix®▼ (Asciminib), the First STAMP Inhibitor for Patients With Chronic Myeloid Leukaemia

Novartis UK has announced that Scemblix® (asciminib) has been granted Marketing Authorisation in Great Britain by […]

New Novartis Data Demonstrate Only Kisqali® Offers More Life in the First-line Setting for Postmenopausal HR+/HER2- Advanced Breast Cancer Patients

Novartis today announced updated median overall survival (OS) results for Kisqali® (ribociclib) in combination with fulvestrant […]

Novartis Tislelizumab plus Chemotherapy Significantly Improved Overall Survival as First-line Treatment for Advanced Esophageal Cancer in Phase III Study

Novartis today announced positive topline results from an interim analysis of the Phase III RATIONALE […]

Novartis Pluvicto™ Approved by FDA as First Targeted Radioligand Therapy for Treatment of Progressive, PSMA-positive Metastatic Castration-resistant Prostate Cancer

Novartis announced today that the US Food and Drug Administration (FDA) approved Pluvicto™ (lutetium Lu […]

Novartis Launches Virtual Innovation Hub to Accelerate Digital Health Solutions in Sub-Saharan Africa

Novartis has announced the launch of its new innovation hub, Novartis Biome sub-Saharan Africa (SSA), […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more